A study by Maude et al.27 discloses that the 6-month EFS rate is 67% and the 6-month OS rate is 78% in R/R B-ALL patients treated with CD19-CAR-T cells with CD3ζ and 4-1BB. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.